[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=4fa4f5c7d5bdc58e53be1628d19ed95291f3f216f926ea9958ae6f8543670613",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734539640,
      "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "id": 132064988,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=4fa4f5c7d5bdc58e53be1628d19ed95291f3f216f926ea9958ae6f8543670613"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know",
    "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=9a87ae05a253de36921f49c1598263c4bb45d9e198b1bb77faff1c679a51fd37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734530422,
      "headline": "Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know",
      "id": 132044362,
      "image": "https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=9a87ae05a253de36921f49c1598263c4bb45d9e198b1bb77faff1c679a51fd37"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s tavapadon achieves positive topline results in Phase III TEMPO-2 trial",
    "summary": "The trial met both its primary endpoint and key secondary endpoint.",
    "url": "https://finnhub.io/api/news?id=307b6dc058e990a1d65948197889511cef1fcdcdfb8af45f86fbb958d8c86217",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734529757,
      "headline": "AbbVie’s tavapadon achieves positive topline results in Phase III TEMPO-2 trial",
      "id": 132041106,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/22/2024/12/PD-cw.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The trial met both its primary endpoint and key secondary endpoint.",
      "url": "https://finnhub.io/api/news?id=307b6dc058e990a1d65948197889511cef1fcdcdfb8af45f86fbb958d8c86217"
    }
  },
  {
    "ts": null,
    "headline": "SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study",
    "summary": "Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.",
    "url": "https://finnhub.io/api/news?id=c3dbdf52256b0c9b2a2a05ed9a878d078889a8162d22f3186a8fdd21ae230695",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734528060,
      "headline": "SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study",
      "id": 132039476,
      "image": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.",
      "url": "https://finnhub.io/api/news?id=c3dbdf52256b0c9b2a2a05ed9a878d078889a8162d22f3186a8fdd21ae230695"
    }
  },
  {
    "ts": null,
    "headline": "Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?",
    "summary": "Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
    "url": "https://finnhub.io/api/news?id=945f12fdf07ed5359dae81708519e6f5975ff748221123a43f036afb6a786e02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734521580,
      "headline": "Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?",
      "id": 132039478,
      "image": "https://media.zenfs.com/en/zacks.com/f562a9c28bce92a6a1caa5408fb2ac68",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
      "url": "https://finnhub.io/api/news?id=945f12fdf07ed5359dae81708519e6f5975ff748221123a43f036afb6a786e02"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys",
    "summary": "Financial writer achieves record dividend income in November through investments in BDCs, inching closer to $10,000 annual goal.",
    "url": "https://finnhub.io/api/news?id=1622bfcd6476b1f6935d84f1ad53065555594e875fe18e2d92fb59ae55233c0a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734509400,
      "headline": "My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys",
      "id": 132038523,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Financial writer achieves record dividend income in November through investments in BDCs, inching closer to $10,000 annual goal.",
      "url": "https://finnhub.io/api/news?id=1622bfcd6476b1f6935d84f1ad53065555594e875fe18e2d92fb59ae55233c0a"
    }
  }
]